Rensair raises $7m in Series A funding led by Hoxton Ventures to expand its air purification business.
Hoxton Ventures led the Series A round to support international growth and product development.
≈ £5.7M at $1 = £0.8194 on 12 May 2022
Rensair develops hospital-grade air purification systems designed for portability and high efficiency across various commercial and residential settings.
Rensair has secured $7m in a Series A financing round led by Hoxton Ventures. The London-based indoor air purification specialist will direct the capital towards global expansion, marketing initiatives, and the rollout of new products equipped with internet of things connectivity. Originally developed for Scandinavian healthcare facilities, the company uses patented technology combining HEPA filtration and ultraviolet light to neutralise airborne pathogens.
From the founder
"The pandemic has taught us that we cannot take air quality for granted, but airborne disease transmission is not the only reason to care about air quality"
Christian Hendriksen
CEO at Rensair
Investor perspective
"Covid has hastened many organisations to proactively address indoor air quality issues to aid in a return to normalcy. Rensair is well-positioned to meet the demands for this growing market."
Hussein Kanji
Partner, Hoxton Ventures
Use of funds
- 01Expand into international markets
- 02Invest in sales and marketing
- 03Continue product development